Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 21;25(3):427-435.
doi: 10.1093/ibd/izy319.

The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information

Arun Swaminath  1 , Eric P Berlin  2 , Adam Cheifetz  3 , Ed Hoffenberg  4 , Jami Kinnucan  5 , Laura Wingate  6 , Sarah Buchanan  7 , Nada Zmeter  8 , David T Rubin  8
Affiliations
Review

The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information

Arun Swaminath et al. Inflamm Bowel Dis. .

Abstract

There is significant interest among patients and providers in using cannabis (marijuana) and its derivatives to treat a number of chronic illnesses, including inflammatory bowel disease. Despite the Schedule I classification of cannabis by the federal government, state governments have sought ways to make cannabis available for specific medical conditions, and some states have legalized cannabis outright. This white paper summarizes the preclinical data, clinical data, safety data, and the regulatory landscape as they apply to medical cannabis use in inflammatory bowel disease. Animal models of cannabinoid chemistry and physiology give evidence of anti-inflammatory, antidiarrheal, and nociceptive-limiting properties. Human studies have found benefit in controlling symptoms and improving quality of life, but no studies have established true disease modification given the absent improvement in biomarker profiles or endoscopic healing. Finally, this review describes the legal, regulatory, and practical hurdles to studying the risks and benefits of medical cannabis in the United States. 10.1093/ibd/izy319_video1 izy319.video1 5852852028001.

Keywords: Crohn’s disease; THC; cannabis; inflammatory bowel disease; marijuana; ulcerative colitis.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Legal status of cannabis by State in the United States—August 2018.
See this image and copyright information in PMC

References

    1. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91–99. - PMC - PubMed
    1. Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014;109:705–714. - PubMed
    1. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338. - PubMed
    1. Rubin DT, Mody R, Davis KL, et al. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1143–1155. - PubMed
    1. Panés J, O’Connor M, Peyrin-Biroulet L, et al. Improving quality of care in inflammatory bowel disease: what changes can be made today?J Crohns Colitis. 2014;8:919–926. - PubMed

Publication types

Substances